Inactive Instrument

Highlights NurExone Biologic Inc. Toronto S.E.

Equities

NurExone Biologic Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 29	CI
NurExone Biologic Announces OTCQB Listing And DTC Eligibility	Apr. 25	MT
NurExone Biologic Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 02	CI
NurExone Biologic Building a Research and Development Facility in Israel	Mar. 08	MT
NurExone Biologic Inc. Establishes Research and Development Facility in Haifa, Israel	Mar. 08	CI
NurExone Biologic Inc. Expands Intellectual Property Portfolio	Feb. 20	CI
NurExone Biologic Inc. Launches Licensing Efforts for ExoTherapy Platform	Feb. 14	CI
NurExone Biologic Provides Operations Update	23-07-20	MT
NurExone Biologic Posts Q1 Net Loss	23-05-24	MT
NurExone Granted U.S. Patent for Technology and Drug Composition of Exo-PTEN, For Acute Spinal Cord Injuries Treatmenet	23-05-16	MT

No results for this search